MADRIGAL PHARMACEUTICALS, INC. (MDGL)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, MADRIGAL PHARMACEUTICALS, INC. reported revenue of $958.40M, up 432.1% from the prior year. The company ran a net loss, with a net margin of -30.1%. It held $1.26B in total assets against $656.90M in total liabilities.
Key ratios (FY2025)
-31.3%
Operating margin
-30.1%
Net margin
-47.8%
Return on equity
+432.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $958.40M | $180.13M | $0 | $0 | — | — | — | — | — | — |
| Cost of Revenue | — | $6.23M | $0 | $0 | — | — | — | — | — | — |
| Operating Income | -$300.10M | -$497.88M | -$380.50M | -$293.57M | -$242.48M | -$206.67M | -$94.97M | -$40.68M | -$32.06M | -$25.22M |
| Net Income | -$288.28M | -$465.89M | -$373.63M | -$295.35M | -$241.85M | -$202.24M | -$83.95M | -$32.81M | -$31.15M | -$26.39M |
| EPS (Diluted) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 | — | — | — | — |
| Total Assets | $1.26B | $1.04B | $640.55M | $362.57M | $273.33M | $287.00M | $442.06M | $485.43M | $192.31M | $41.21M |
| Total Liabilities | $656.90M | $287.86M | $235.21M | $165.18M | $77.22M | $47.02M | $25.49M | $8.44M | $10.05M | $4.80M |
| Shareholders' Equity | $602.69M | $754.38M | $405.33M | $197.39M | $196.11M | $239.97M | $416.56M | $476.98M | $182.26M | $36.41M |
| Cash & Equivalents | $198.69M | $100.02M | $99.92M | $331.55M | $36.27M | $54.00M | $46.70M | $57.38M | $148.63M | $19.14M |
| Operating Cash Flow | -$189.55M | -$455.57M | -$324.23M | -$224.86M | -$183.92M | -$157.56M | -$41.62M | -$25.51M | -$22.32M | -$17.61M |
| Capital Expenditures | $467.0K | $1.46M | $1.48M | $217.0K | $209.0K | $334.0K | $172.0K | $22.0K | $125.0K | $3.0K |
| Shares Outstanding | 22.84M | 22.00M | 19.88M | 18.10M | 17.10M | 15.51M | 15.43M | 15.41M | 14.23M | 11.95M |